Reviewing Orchestra BioMed (NASDAQ:OBIO) and NeurAxis (NASDAQ:NRXS)

Orchestra BioMed (NASDAQ:OBIO) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and target prices for Orchestra BioMed and NeurAxis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1	0	6	0	2.71
NeurAxis	0	1	1	0	2.50

Orchestra BioMed presently has a consensus price target of $13.17, suggesting a potential upside of 126.43%. NeurAxis has a consensus price target of $13.00, suggesting a potential upside of 65.61%. Given Orchestra BioMed’s stronger consensus rating and higher possible upside, research analysts plainly believe Orchestra BioMed is more favorable than NeurAxis.

Volatility & Risk

Orchestra BioMed has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.

Profitability

This table compares Orchestra BioMed and NeurAxis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-184.60%	-149.61%	-54.15%
NeurAxis	-492.76%	N/A	-641.25%

Valuation and Earnings

This table compares Orchestra BioMed and NeurAxis”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48 million	10.44	-$52.70 million	($0.85)	-6.84
NeurAxis	$5.32 million	18.54	-$14.63 million	($0.78)	-10.06

NeurAxis has lower revenue, but higher earnings than Orchestra BioMed. NeurAxis is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by company insiders. Comparatively, 21.1% of NeurAxis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.